Literature DB >> 20121419

Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

Jeffrey T Schouten1, Amy Krambrink, Heather J Ribaudo, Anne Kmack, Nancy Webb, Cecilia Shikuma, Daniel R Kuritzkes, Roy M Gulick.   

Abstract

In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20121419      PMCID： PMC2975665          DOI： 10.1086/650539

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  8 in total

1.  Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.

Authors:  Douglas J Ward; John M Curtin
Journal:  AIDS Patient Care STDS       Date:  2006-08       Impact factor: 5.078

2.  Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Christina Lalama; Bruce R Schackman; William A Meyer; Edward P Acosta; Jeffrey Schouten; Kathleen E Squires; Christopher D Pilcher; Robert L Murphy; Susan L Koletar; Margrit Carlson; Richard C Reichman; Barbara Bastow; Karin L Klingman; Daniel R Kuritzkes
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

3.  Design issues in initial HIV-treatment trials: focus on ACTG A5095.

Authors:  Heather J Ribaudo; Daniel R Kuritzkes; Bruce R Schackman; Edward P Acosta; Cecilia M Shikuma; Roy M Gulick
Journal:  Antivir Ther       Date:  2006

4.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

5.  Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.

Authors:  Amanda Mocroft; Schlomo Staszewski; Rainer Weber; José Gatell; Jurgen Rockstroh; Jacek Gasiorowski; George Panos; Antonella d'Arminio Monforte; Aza Rakhmanova; Andrew N Phillips; Jens D Lundgren
Journal:  Antivir Ther       Date:  2007

Review 6.  Is it safe to switch between efavirenz and nevirapine in the event of toxicity?

Authors:  Ushma Mehta; Gary Maartens
Journal:  Lancet Infect Dis       Date:  2007-11       Impact factor: 25.071

7.  Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.

Authors:  Anouk M Kesselring; Ferdinand W Wit; Caroline A Sabin; Jens D Lundgren; M John Gill; Jose M Gatell; Andri Rauch; Julio S Montaner; Frank de Wolf; Peter Reiss; Amanda Mocroft
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

Review 8.  Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.

Authors:  J Ena; A Leach; P Nguyen
Journal:  HIV Med       Date:  2008-07-21       Impact factor: 3.180
  8 in total
  12 in total

1.  Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.

Authors:  Reshmie Ramautarsing; Jintanat Ananworanich
Journal:  AIDS Res Ther       Date:  2010-06-23       Impact factor: 2.250

Review 2.  EFV/FTC/TDF-associated hepatotoxicity: a case report and review.

Authors:  Ignacio A Echenique; Josiah D Rich
Journal:  AIDS Patient Care STDS       Date:  2013-08-12       Impact factor: 5.078

3.  Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.

Authors:  Paul D Sonenthal; Bakgaki Ratshaa; Gilbert Chimbengo; Tumelo Rantleru; Thelma Ngoni; Sarah Barenbaum; Rebecca Platoff; Andrew P Steenhoff; Robert Gross
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03-24       Impact factor: 2.890

4.  HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

Authors:  Manuela G Neuman; Michelle Schneider; Radu M Nanau; Charles Parry
Journal:  Int J Hepatol       Date:  2012-03-11

5.  Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.

Authors:  Josep M Llibre; Isabel Bravo; Arelly Ornelas; José R Santos; Jordi Puig; Raquel Martin-Iguacel; Roger Paredes; Bonaventura Clotet
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

6.  Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.

Authors:  Jackson K Mukonzo; Alphonse Okwera; Neoline Nakasujja; Henry Luzze; Deogratious Sebuwufu; Jasper Ogwal-Okeng; Paul Waako; Lars L Gustafsson; Eleni Aklillu
Journal:  BMC Infect Dis       Date:  2013-06-04       Impact factor: 3.090

7.  New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.

Authors:  Nimish Patel; Christopher D Miller
Journal:  HIV AIDS (Auckl)       Date:  2012-04-27

8.  Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report.

Authors:  Mette S van Ramshorst; Magdeline Kekana; Helen E Struthers; James A McIntyre; Remco P H Peters
Journal:  BMC Pediatr       Date:  2013-08-13       Impact factor: 2.125

9.  The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD).

Authors:  In Young Jung; David Boettiger; Wing Wai Wong; Man Po Lee; Sasisopin Kiertiburanakul; Romanee Chaiwarith; Anchalee Avihingsanon; Junko Tanuma; Nagalingeswaran Kumarasamy; Adeeba Kamarulzaman; Fujie Zhang; Pacharee Kantipong; Oon Tek Ng; Benedict Lim Heng Sim; Matthew Law; Jeremy Ross; Jun Yong Choi
Journal:  J Int AIDS Soc       Date:  2017-12       Impact factor: 5.396

10.  Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.

Authors:  Alessandro Schipani; David Back; Andrew Owen; Gerry Davies; Saye Khoo; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 5.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.